{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32.1","upperLimit":"58.4","value":"45.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"title":"RBC and platelet transfusion independence"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"31.6","upperLimit":"59.6","value":"45.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"}],"units":"Participants"}],"title":"RBC transfusion independence"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"38.5","upperLimit":"80.3","value":"60.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"}],"units":"Participants"}],"title":"Platelet transfusion independence"}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"Post baseline transfusion independence rate was estimated as the percentage of participants who achieved transfusion independence during the evaluation period. Post-baseline transfusion independence is defined as a period of at least 56 days (≥ 56 days) with no RBC or platelet transfusion during the evaluation period. The evaluation period is from the first dose of study drug to the last dose of study drug until the 30 day follow-up visit, disease progression (including clinical progression), or death, whichever was earlier.\n\nResults are reported for participants who achieved both RBC and platelet transfusion independence and for participants who received RBC transfusion independence and platelet transfusion independence.","dispersionType":"95% Confidence Interval","groups":[{"description":"Venetoclax was administered orally once daily (QD) on Days 2 through 28 of Cycle 1. Dosing started at 50 mg, and increased up to 600 mg by Day 6. Beginning with Cycle 2, 600 mg venetoclax was administered Days 1 through 28 of each 28-day cycle. Participants also received LDAC (20 mg/m²) administered by subcutaneous injection once daily on Days 1 to 10 of each cycle.\n\nParticipants could continue receiving treatment until disease progression or until discontinuation criteria were met.","id":"OG000","title":"Phase 1+2: 600 mg Venetoclax + LDAC"}],"paramType":"NUMBER","populationDescription":"Enrolled participants who received venetoclax with LDAC at the recommended Phase 2 dose (600 mg) who received a RBC or platelet transfusion within 8 weeks prior to first dose (60), an RBC transfusion within 8 weeks prior to first dose (53) or a platelet transfusion within 8 weeks prior to first dose (23).","reportingStatus":"POSTED","timeFrame":"From the first dose of study drug to the last dose of study drug plus 30 days, disease progression (including clinical progression), or death, whichever was earlier; median duration of treatment was 4.2 months.","title":"Post Baseline Transfusion Independence Rate Among Participants Transfusion-dependent at Baseline","type":"SECONDARY","unitOfMeasure":"percentage of participants"}